市場調査レポート
商品コード
1297818
血管形成術用バルーンの世界市場-2023年~2030年Global Angioplasty Balloons Market - 2023-2030 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
血管形成術用バルーンの世界市場-2023年~2030年 |
出版日: 2023年06月15日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
|
血管形成術用バルーンの世界市場は、2022年に22億米ドルに達し、2030年には29億米ドルに達するなど、有利な成長が予測されています。血管形成術用バルーンの世界市場は、予測期間中(2023-2030年)に3.5%のCAGRを示すと予測されています。
血管形成術用バルーンは、主に冠動脈疾患(CAD)の治療に使用されます。冠動脈疾患は、動脈内にプラークが蓄積することで発症し、狭窄や閉塞につながります。バルーンによる血管形成術は低侵襲の手技であり、多くの場合鼠径部や手首などの皮膚を小さく切開して行うことができます。
生活習慣病の増加や低侵襲手術に対する需要の高まりといった要因が、市場を牽引すると予想されています。さらに、血管形成術の分野では、特に先進国において、薬剤溶出バルーンやカッティングバルーンなどの先端技術が急速に採用されており、市場推計・予測期間を通じて市場の成長を促進すると予測されます。
企業戦略と研究開発への注目の高まりが市場成長の原動力となります。例えば、2021年6月17日、Sectoral Asset Management社は、独自のセレーション技術を用いた次世代血管形成術用バルーンを製造するCagent Vascular Inc.に900万米ドルの投資を行っています。今回の出資に加え、Marc-Andre Marcotte氏が取締役に就任しました。この資金は、セラネーター膝下型(BTK)製品の商業化と規模拡大を促進するために使用されます。
さらに2022年4月22日、アキュメッド・ラジアル・システムズ社はPOBA Medical, Inc.と戦略的契約を締結し、当社の革新的で独自かつ画期的なアキュメッド・ラジアル血管内延長術(ARIVE)技術のプロトタイプを作成することを発表しました。POBA社はAccumed Radialチームと協力し、設計、製造、スケールアップの専門知識を提供しながら、複数の用途に対応するARIVEのプロトタイプを作成します。POBAは同時にアキュメッド・ラディアルに出資します。前述の要因は、予測期間中の市場拡大を促進すると予測されます。
末梢動脈疾患および冠動脈疾患は、動脈硬化の頻繁な症状であり、脳卒中、心筋梗塞、および/または心血管疾患による死亡につながる可能性があります。これらの疾患の有病率の上昇は、今後数年間の市場拡大を促進すると予想されます。CDCによると、冠動脈性心疾患は最も頻度の高い心臓病であり、2021年までに約37万5千人が死亡します。CADは20歳以上の約20人に1人が罹患します。
2021年には、CADによる死亡者10人のうちほぼ2人が65歳未満で死亡することになります。その結果、冠動脈性心疾患は増加傾向にあり、市場の成長に寄与しています。
血管形成術に伴う高コストと術後の困難が市場拡大を阻害すると予想されます。国立医学図書館によると、外来患者料金を含む1回の手術あたりの平均総料金は2万1,893米ドルで、血管形成術後6~10時間以内に再狭窄、心臓発作、心室細動、心筋梗塞、ステントの誤留置、動脈瘤、腎不全、発作などの合併症が発生しています。これらの要素は市場の成長を妨げる可能性が高いです。
2020年9月に発表された研究によると、現在のCOVID-19パンデミック時の心臓手術は、COVID-19による合併症のリスクが高くなった心臓病患者と、これらの患者のケアをするヘルスケアスタッフの両方に複合的な危険をもたらします。さらに、米国外科学会と米国麻酔科学会は、COVID-19の検査結果が出た後、少なくとも14日間は選択的心臓手術を延期することを推奨しています。
COVID-19をめぐるさまざまな配慮の結果、選択的血管形成術は一時中断され、血管形成術用バルーンの使用に影響が及ぶと予測されます。この期間中、市場はほとんど成長しない可能性があります。
ロシア・ウクライナは、血管形成術用バルーンの普及率が低く、主要な市場プレーヤーが存在しないため、世界の血管形成術用バルーン市場に与える影響は最小限と推定されます。しかし、原材料、試験製品、デバイスの輸出入の影響は、予測期間中、血管形成術用バルーンの世界市場にほとんど影響を与えないと予想されます。
人工知能は、世界の血管形成用バルーン市場にプラスの影響を与えると予測されます。AIアルゴリズムは、血管造影やコンピュータ断層撮影(CTA)スキャンなどの医療画像を分析して、血管内の病変や閉塞の特定や局在化を支援することができます。
この解析は、閉塞の大きさ、位置、重症度に関する洞察を提供することにより、インターベンショナル・カーディオロジストが血管形成術を計画する際に役立つ。AIは血管形成術のバルーン手技を支援する上で大きな可能性を示しているが、医療専門家の専門知識や判断に取って代わるものではなく、医療専門家を支援するツールとして常に使用されるべきであることに注意することが重要です。
The Global Angioplasty Balloons Market reached US$ 2.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 2.9 billion by 2030. The global angioplasty balloons market market is expected to exhibit a CAGR of 3.5% during the forecast period (2023-2030).
Angioplasty balloons are primarily used in the treatment of coronary artery disease (CAD), which occurs due to the buildup of plaque within the arteries, leading to their narrowing or blockage. Angioplasty with balloons is a minimally invasive procedure that can be performed through a small incision in the skin, often in the groin or wrist area.
Factors such as the increased occurrence of lifestyle-related disorders and the increasing demand for minimally invasive procedures are anticipated to propel the market. Moreover, the Rapid adoption of advanced technologies, particularly in the developed world, in the angioplasty segment, including such drug-eluting and cutting balloons, is estimated to drive market growth throughout the forecast period.
The increased focus on companies strategies and R&D will drive the market growth. For instance, on June 17, 2021, Sectoral Asset Management has made a $9 million investment in Cagent Vascular Inc., a producer of next generation angioplasty balloons using unique serration technology. Marc-Andre Marcotte has joined the board of directors in addition to the investment. The funds will be used to expedite the commercialization and scaling of the Serranator below-the-knee (BTK) product.
Additionally, on April 22, 2022, Accumed Radial Systems announce a strategic agreement with POBA Medical, Inc. to create prototypes of our innovative, proprietary, and game-changing Accumed Radial Intra Vascular Extension (ARIVE) technology. POBA will collaborate with Accumed Radial teams to build ARIVE prototypes for multiple applications, while providing design, manufacturing, and scale-up expertise. POBA will invest in Accumed Radial at the same time. The aforementioned factors are projected to fuel market expansion over the forecast period.
Peripheral and coronary artery disease are frequent symptoms of atherosclerosis and can lead to stroke, myocardial infarction, and/or death from cardiovascular disease. The rising prevalence of these disorders is expected to drive market expansion in the following years. According to the CDC, coronary heart disease is the most frequent type of heart disease, killing around 375,000 individuals by 2021. CAD affects about one in every twenty persons aged 20 and over.
In 2021, almost 2 out of every 10 deaths from CAD will occur in persons under the age of 65. As a result, coronary heart disease is on the rise, contributing to market growth.
High costs and post-operative difficulties associated with angioplasty are expected to stifle market expansion. According to the National Library of Medicine, the average total charge per procedure, including outpatient charges, was $21,893, and complications such as restenosis, heart attack, ventricular fibrillation, myocardial infarction, misplacement of a stent, aneurysms, kidney failure, and seizures occurred within 6 to 10 hours of angioplasty. These elements are likely to hinder market growth.
According to a study released in September 2020, cardiac surgery during the present COVID-19 pandemic poses a combined danger for both cardiac patients, who are now at a higher risk of complications due to COVID-19, and the healthcare staff who care for these patients. Furthermore, the American College of Surgeons and the American Society of Anesthesiologists recommended postponing elective heart surgery for at least 14 days following a COVID-19 test result.
As a result of the various considerations surrounding COVID-19, elective angioplasty surgeries are projected to be suspended, affecting the use of angioplasty balloons. During this period, the market may experience little, if any are present, growth.
The Russia-Ukraine is estimated to have a minimal impact on the global angioplasty balloons market owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials, test products, and devices is anticipated to have little influence over the global angioplasty balloons market in the forecast period.
Artificial intelligence is anticipated to impact the global angioplasty balloons market positively . Due to AI algorithms can analyze medical images, such as angiograms or computed tomography angiography (CTA) scans, to assist in the identification and localization of lesions or blockages within the blood vessels.
This analysis helps the interventional cardiologist in planning the angioplasty procedure by providing insights into the size, location, and severity of the blockage. It's important to note that while AI shows great potential in assisting with angioplasty balloon procedures, it should always be used as a tool to support healthcare professionals rather than a replacement for their expertise and judgment.
The global angioplasty balloons market is segmented based on product type, application, end user, and region.
The hospital segment holds about 34.5% of the total angioplasty balloons market in the forecast period. The significant increase in the older population suffering from lifestyle disorders including atherosclerosis and heart failure is predicted to increase the patient pool and boost hospital income production. Furthermore, as compared to traditional operations, the numerous benefits of minimally invasive surgeries, such as reduced surgical discomfort, injury, scarring, hospital stay, higher accuracy, and faster recovery time, motivate more patients to choose minimally invasive balloon angioplasty surgeries.
For instance, according to the American College of Cardiology, roughly 2.1 million angioplasties are performed in the United States per year in 2020. Furthermore, hospitals are likely to attract a big patient base due to their greater accessibility and affordability when compared to speciality clinics. All of these factors are projected to have an impact on segment growth.
The North America region holds the largest share of the global angioplasty balloons market accounting for approximately 40.1% in the forecast period. North America accounted for the maximum revenue share in the angioplasty balloons market. The presence of key industry players, the rising healthcare expenditure, and the increasing product approvals by regulatory bodies in the United States are expected to drive the market's growth.
For instance, on January 2, 2023, the Stellarex 0.035 OTW Drug-coated Angioplasty Balloon from Philips Image Guided Therapy Corp. has been approved by the US Food and Drug Administration (FDA). Stellarex 0.035 OTW Drug-coated angioplasty balloon (Stellarex 035 DCB) reopens blocked or restricted arteries in the thigh and knee caused by peripheral arterial disease (PAD). These advancements are projected to strengthen the region's market's robust product portfolio.
The major global players in the market include: Boston Scientific Corporation, BIOTRONIK, Medtronic Plc, Cordis (Cardinal Health), Terumo Corporation, Abbott Laboratories, AngioDynamics, BD, INFINITY Angioplasty Balloon, and Koninklijke Philips N.V, among others.
The global angioplasty balloons market report would provide approximately 53 tables, 54 figures, and 195 Pages.
LIST NOT EXHAUSTIVE